Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Which numbing cream eases laser pain best? new study puts two top contenders to the test

NCT ID NCT02427724

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests two different numbing creams—one with lidocaine/prilocaine and another with lidocaine/tetracaine—against a placebo to see which works best for pain during Q-switched 532nm laser treatment for age spots (lentigines) and skin rejuvenation. Women aged 25 to 65 with mild to moderate sun damage will have each cream applied to different areas of their face or body before laser treatment. They will rate their pain on a 0-to-10 scale after each area is treated, helping researchers find the most effective option for comfort.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lidocaine 2.5%/prilocaine 2.5% cream and lidocaine 7%/tetracaine 7% cream
What this could lead to
If one cream works better, it could make laser skin treatments less painful for people with age spots or sun damage.
What could go wrong
This is a very early study with only 48 women, so results may not apply to everyone. Pain relief varies by person, and both creams can cause skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Apr 2015

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 65 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients who have moderate lentigines and/or photodamage and desire laser toning. 2. Females 25-65 years of age. 3. In good health. 4. Have Fitzpatrick phototype I-III. 5. Willingness and the ability to understand and provide informed consent and communicate with the investigator/study staff. Exclusion Criteria: 1. Younger than 25 or older than 65 years of age. 2. Pregnant or lactating. 3. Is a male. 4. Has received the following treatments on the face: * ablative or non-ablative laser procedure in the past 3 months * radiofrequency device treatment in the past 3 months * ultrasound device treatment in the past 3 months * medium to deep chemical peel in the past 3 months 5. Has an active infection on the face or upper inner arms (excluding mild acne). 6. Is allergic to lidocaine, tetracaine, or prilocaine. 7. Has kidney disease and/or liver disease. 8. Has G-6-PD and/or pseudocholinesterase deficiency. 9. Is taking a class I anti-arrhythmic medication. 10. Is tanned. 11. Has a history of hyperpigmentation with laser treatment. 12. Has a mental illness. 13. Has a history of a chronic pain condition such as fibromyalgia or vulvodynia. 14. Unable to understand the protocol or to give informed consent. 15. Multiply recurrent episodes of cold sores. 16. Any significant skin disease beyond mild acne. 17. Any other condition that would, in the professional opinion of the investigator, potentially affect response or participation in the clinical clinical study, or would pose as an unacceptable risk to the subject.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lentigo are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Northwestern University Feinberg School of Medicine, Department of Dermatology

    Chicago, Illinois, 60611, United States